tion as a rare and unusual cause of heart failure.
The disease has long enjoyed a "zebra" cachet owing More recently, cardiac involvement could be diagnosed by a histological identification of amyloidosis from another body site in the context of supportive noninvasive cardiac imaging findings as determined by echocardiography, magnetic resonance imaging, or nuclear scintigraphy (bone avid tracers) (6) . Of these noninvasive tests, only nuclear imaging has the capacity to definitively demonstrate ATTR cardiac amyloidosis without a tissue biopsy (7) . Although conclusively shown to be highly sensitive and specific among patients with suspected amyloidosis (8) , to date, no screening studies using nuclear imaging have been reported. However, ATTR amyloidosis has been demonstrated in up to 13% of patients with heart failure and preserved ejection fraction with increased LV wall thickness (9) , 16% of patients with severe aortic stenosis undergoing transcutaneous valve replacement (10), 5% of patients with presumed hypertrophic cardiomyopathy (11) , and in 1% to 2% of subjects undergoing bone scintigraphy for noncardiac reasons (12) . These observations challenge the conception that ATTR amyloidosis, in particular, is a rare disease.
Because amyloidosis is a systemic disease with deposition that has also classically been associated with carpal tunnel syndrome (CTS) (13), Sperry et al. (14) from Eidos Therapeutics. 
